
Part 1
Part 2
Double-blind treatment period
(24 weeks)
Part 3
Open-label extension
(5 years)
Dose escalation of
Ruxolitinib-naïve
Part 1 (n=6)
(N=212)
R
2:1
Avapritinib 25 mg QD
(n=141)
Placebo
(n=71)
All Part 1 and 2 patients on
avapritinib (ongoing)

Figure 1